Aligos Therapeutics reports Q3 EPS ($3.04), consensus ($2.01)

Reports Q3 revenue $741k, consensus $500k. “Our Phase 2 B-SUPREME study of pevifoscorvir sodium is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China, Hong Kong, and Canada,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics (ALGS). “We are pleased with the progress to date and look forward to interim readouts in 2026. Importantly, we look forward to sharing additional pevy data next week at AASLD’s The Liver Meeting. We maintain our enthusiasm regarding the potential for pevy as well as our entire development pipeline, including ALG-055009, which is in continued discussions with potential partners for obesity and MASH.”